These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 20738228)

  • 1. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
    Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
    Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.
    Saini SD; Fendrick AM; Scheiman JM
    Aliment Pharmacol Ther; 2011 Jul; 34(2):243-51. PubMed ID: 21615437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
    Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
    Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of U.S. guidelines in other countries: aspirin for the primary prevention of cardiovascular events in Japan.
    Morimoto T; Fukui T; Lee TH; Matsui K
    Am J Med; 2004 Oct; 117(7):459-68. PubMed ID: 15464702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.
    Ademi Z; Liew D; Hollingsworth B; Steg PG; Bhatt DL; Reid CM;
    Cardiovasc Ther; 2013 Feb; 31(1):45-52. PubMed ID: 21884025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
    Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aspirin for the prevention of cardiovascular disease: recommendation statement.
    Am Fam Physician; 2011 Jun; 83(12):1464-8. PubMed ID: 21671547
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost-effectiveness model of use of genetic testing as an aid in assessing the likely benefit of aspirin therapy for primary prevention of cardiovascular disease.
    Shiffman D; Slawsky K; Fusfeld L; Devlin JJ; Goss TF
    Clin Ther; 2012 Jun; 34(6):1387-94. PubMed ID: 22560621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
    Annemans L; Wittrup-Jensen K; Bueno H
    J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Budget Impact of Appropriate Low-Dose Aspirin Use for Primary and Secondary Cardiovascular Event Prevention in the Managed Care Setting.
    Carlton R; Coppolecchia R; Khalaf-Gillard K; Lennert B; Moradi A; Williamson T; Cameron J
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1102-1111. PubMed ID: 30362916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
    Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
    Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the primary prevention of adverse cardiovascular events.
    Estes K; Thomure J
    Crit Care Nurs Q; 2008; 31(4):324-39. PubMed ID: 18815480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and practice-level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry.
    Hira RS; Kennedy K; Nambi V; Jneid H; Alam M; Basra SS; Ho PM; Deswal A; Ballantyne CM; Petersen LA; Virani SS
    J Am Coll Cardiol; 2015 Jan; 65(2):111-21. PubMed ID: 25593051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal bleeding during low-dose aspirin administration for prevention of arterial occlusive events. A critical analysis.
    Stalnikowicz-Darvasi R
    J Clin Gastroenterol; 1995 Jul; 21(1):13-6. PubMed ID: 7560825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin for primary prevention: do potential benefits outweigh the risks?
    Shakib S
    Intern Med J; 2009 Jun; 39(6):401-7. PubMed ID: 19580619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.